CompoAtlas

MixNatural and Herbal Formula Menopause Free Capsule

Testo originale in francese.

Prodotto naturale per la salute autorizzato in Canada

Se questo prodotto fosse venduto in Francia

Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.

Composizione

Ingrediente medicinale e fontePer unità posologica, secondo la fonteMassimo giornaliero, adulto
Vitex agnus-castus

Fonte : Fruit

34 mgNon calcolata
Glycyrrhiza glabra

Fonte : Racine

50 mgNon calcolata
Glycine max

Fonte : Glycine max - Graine

Potenza : 11 mg ÉAI Isoflavones

55 mgNon calcolata
Angelica sinensis

Fonte : Racine

50 mgNon calcolata
Actaea racemosa

Fonte : Racine

54 mgNon calcolata
Actaea racemosa

Fonte : Rhizome

54 mgNon calcolata

Ingredienti non medicinali

Gélatine, Stéarate de magnésium, Maltodextrine

Dosi raccomandate in Canada

PopolazioneEtàQuantità per assunzioneFrequenza
Adultes de sexe fémininNon précisée1 Capsule1 Tous les jours

Usi autorizzati in Canada

Used in Herbal Medicine to help relieve premenstrual symptoms. Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flashes.

Testo originale in inglese.

Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.

Avvertenze in Canada

Cautions and Warnings : Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you have a liver disorder or develop liver trouble. Consult a health care practitioner prior to use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (HRT), including thyroid replacement therapy. Ensure that you are up-to-date on mammograms and gynaecological evaluations prior to use. Consult a health care practitioner prior to use if you are taking blood thinners. Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including ovarian cancer, endometriosis, and/or uterine fibroids. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting. Do not use if you currently have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or a family member with breast cancer. Do not use if you are taking thiazide diuretics, cardiac glycosides, corticosteroids, stimulant laxatives or other medications which may aggravate electrolyte imbalance. Do not use if you have hypokalemia, high blood pressure, or a kidney or cardiovascular disorder. Avoid prolong exposure to sunlight ultraviolet light (UV) or UV therapy. Discontinue use and consult a health care practitioner if menstruation is delayed or absent, or if you experience increased menstrual bleeding time.

Testo originale in inglese.

Contra-Indications : Do not use if you are pregnant. Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician.

Testo originale in inglese.

Scheda del prodotto

Altri nomi
MapleLife Menopause Free Capsule, Menopause Support Complex
Titolare
Nutralab Canada Corp.
NPN o DIN-HM
80029933
Stato
Licenza attiva
Data della licenza
28 febbraio 2012
Data di revisione
11 marzo 2025
Forma
Capsule
Via di somministrazione
Orale
Tipo di domanda
Non traditionnelle

Fonte

Scheda ufficiale Health Canada, licenza 80029933

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Testo originale in inglese.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Testo originale in francese.

La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Vitex agnus-castus
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    CHASTE TREE - VITEX AGNUS-CASTUS

    Via di somministrazione: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).

    Fonti citate da Health Canada (4)
    • Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Controindicazioni

    Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).

    Fonti citate da Health Canada (9)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
    • Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Monografia di Health Canada del 28 marzo 2024

  • Glycyrrhiza glabra
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    DEGLYCYRRHIZINATED LICORICE Buccal

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 31 ottobre 2025

    Deglycyrrhizinated Licorice Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 31 gennaio 2025

    LICORICE

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    Fonti citate da Health Canada (1)
    • Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.

    Condizione di applicazione: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    Fonti citate da Health Canada (1)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf

    Condizione di applicazione: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Controindicazioni

    Condizione di applicazione: All products.

    Do not use if you are pregnant (EMA 2012).

    Fonti citate da Health Canada (2)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    Fonti citate da Health Canada (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    Fonti citate da Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Monografia di Health Canada del 29 novembre 2024

  • Glycine max
    Leggere l'avvertenza, quando si applica e gli studi citati
  • Angelica sinensis
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    DONG QUAI - ANGELICA SINENSIS

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (NS 2021).

    Fonti citate da Health Canada (1)
    • NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936

    Ask a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking any medications including blood thinners, birth control pills or hormone therapy (NS 2021; Brinker 2010; WHO 2002).

    Fonti citate da Health Canada (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
    • WHO 2002: World Health Organization Monographs on Selected Medicinal Plants - Volume 2. Geneva (CH): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la santé. Monographs on Selected Medicinal Plants - Volume 2. Genève (CH): Organisation mondiale de la santé; 2002.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have serious or major conditions, any type of acute infection, deficiency or excess (HC 2022).

    Fonti citate da Health Canada (2)
    • HC 2022: Health Canada. Traditional Chinese Medicine Ingredients monograph. [Accessed 2024 July 10]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=tcm&lang=eng
    • SC 2022: Santé Canada. Monographie sur les Ingrédients de la Médecine Traditionnelle Chinoise. [Consulté le 10 juillet 2024]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=tcm&lang=fre

    When using this product avoid exposure to the sun (NS 2021; Thorne 2004).

    Fonti citate da Health Canada (2)
    • NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
    • Thorne 2004: Thorne Research Inc. Monograph Angelica sinensis (Dong quai). Alternative Medicine Review 2004;9(4):429-433.

    Controindicazioni

    Do not use if you are pregnant (NS 2021; WHO 2002).

    Fonti citate da Health Canada (4)
    • NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
    • WHO 2002: World Health Organization Monographs on Selected Medicinal Plants - Volume 2. Geneva (CH): World Health Organization; 2002.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
    • OMS 2002: Organisation mondiale de la santé. Monographs on Selected Medicinal Plants - Volume 2. Genève (CH): Organisation mondiale de la santé; 2002.

    Do not use if you have diarrhea, hemorrhagic diseases or heavy periods (NS 2021, Bensky et al. 2004; Chen and Chen 2004; WHO 2002).

    Fonti citate da Health Canada (6)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.
    • NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
    • WHO 2002: World Health Organization Monographs on Selected Medicinal Plants - Volume 2. Geneva (CH): World Health Organization; 2002.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
    • OMS 2002: Organisation mondiale de la santé. Monographs on Selected Medicinal Plants - Volume 2. Genève (CH): Organisation mondiale de la santé; 2002.

    Reazioni avverse note

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen, or if new symptoms develop such as breast pain or any changes in menstrual cycles (Brinker 2010; Schumacher et al. 2007; Thorne 2004; Russell et al. 2002).

    Fonti citate da Health Canada (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Russell L, Hicks GS, Low AK, Shepherd JM, Brown CA. Phytoestrogens: a viable option? The American Journal of the Medical Sciences 2002;324(4):185-188. PubMed Articolo di revisione
    • Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, Akwa Y, Rajkowski K, and Baulieu E. Novel perspectives for progesterone in Hormone Replacement Therapy, with special reference to the nervous system. Endocrine Reviews 2007;28:387-439. PubMed Articolo di revisione
    • Thorne 2004: Thorne Research Inc. Monograph Angelica sinensis (Dong quai). Alternative Medicine Review 2004;9(4):429-433.

    Monografia di Health Canada del 29 maggio 2026

  • Actaea racemosa
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    Black Cohosh - Actaea Racemosa

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).

    Fonti citate da Health Canada (6)
    • Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause: the Journal of the North American Menopause Society 2004;11(5):575-577. PubMed Caso clinico
    • EMA 2018: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). European Union Herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. March 2018. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
    • EMA 2007: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) Annex 1. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root). London (UK): European Medicines Agency; May 20027. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf
    • Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transplantation 2006;12(6):989-992. PubMed Caso clinico
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. New York (NY): Taylor and Francis; 2006.
    • NIH 2004: National Institutes of Health. Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD): National Institutes of Health, Department of Health and Human Services; November 22, 2004. [Accessed 2024 December 3]. Available from: https://files.nccih.nih.gov/s3fs-public/news/blackcohosh_mtngsumm.pdf

    Controindicazioni

    Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).

    Fonti citate da Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
    • Tilgner S. Herbal Medicine from the Heart of the Earth Creswell (OR): Wise Acre Press; 1999.

    Monografia di Health Canada del 31 gennaio 2025

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).

Il prodotto è cambiato? Fotografi la confezione.

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Invio per analizzare, Maiusc+Invio per una nuova riga